Pure Global AI
NCT06105684Not yet recruiting

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

University of Alabama at BirminghamPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Metastatic Breast Cancer
Drug/Device/Intervention
Capecitabine Pill
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Alabama at Birmingham
Location
Birmingham, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2024
End date
Dec 01, 2028
Enrollment
40 participants
Primary outcome

Response rate (RR) evaluation

Summary

This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg
 once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any
 age, with a greater risk of complications and poorer outcomes with other treatments.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastMalignant neoplasm: Overlapping lesion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06105684
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06105684 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.